Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
CLIN.L Share News (CLIN)
CLIN Share
Price
CLIN Share
News
CLIN Share
Chat
CLIN Share
Trades
CLIN
Live RNS
CLIN Share
Charts
CLIN Broker
Ratings
CLIN Directors
Deals
CLIN Financial
Diary
CLIN
Fundamentals
CLIN Short
Positions
CLIN
Media
CLIN Company
Research
CLIN Company
Timeline
- There is currently no data for CLIN
Clinigen reiterates guidance after 'solid' first half
The AIM-traded firm said that as usual, it expected to see a second-half weighting to the full-year numbers.
It said its leverage on 31 December was expected to be 2.5x, "meaningfully below" the group's temporary banking covenant of 3.5x.
"During the first half of the year we have seen a solid performance across both the services and products divisions," said group chief executive officer Shaun Chilton.
"We remain mindful of the continued prevalence of the Covid-19 Omicron variant, which has the potential to impact our principal markets.
"However, we continue to perform well on those elements within our control and remain focussed on building the lifecycle platform to service the needs of pharma companies and healthcare professionals around the globe."
At 1115 GMT, shares in Clinigen Group were down 0.54% at 917p.
Latest CLIN News
- Thursday broker round-up
23 Jul 2020 - Clinigen Annual Profit Rise To Be At Lower End Of Guidance
14 Jul 2020 - UK BROKER RATINGS SUMMARY: RBC Upgrades IMI And Downgrades Rotork
14 Jul 2020 - Clinigen FY revenues continue to rise, profit growth slowed by Covid-19
14 Jul 2020 - Clinigen gets orphan drug designation for 'aldesleukin' in the US
13 Jul 2020 - Monday broker round-up
13 Jul 2020 - Clinigen Gets US Orphan Drug Designation For ALS Treatment Aldesleukin
13 Jul 2020 - Sunday newspaper round-up: Two meters, Rolls Royce, Clinigen
14 Jun 2020
Related News
IN BRIEF: UK court sanctions Titon takeover of Clinigen
Clinigen Group PLC - Burton On Trent, Staffordshire-based pharmaceutical services - Says Thursday that its takeover by Triton Investment Management Lt...
AIM faces trading volume cliff as three most active stocks exit
(Alliance News) - The three most active stocks on the AIM market in London are set to depart all at once, potentially leaving a gap in trading volume ...
TRADING UPDATES: IPF swings to profit; Seraphine lowers outlook
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:
CLIN.L News
Thursday broker round-up
(Sharecast News) - Stagecoach Group: Peel Hunt upgrades to buy with a target price of 70.0p.
Clinigen Annual Profit Rise To Be At Lower End Of Guidance
Clinigen Annual Profit Rise To Be At Lower End Of Guidance
UK BROKER RATINGS SUMMARY: RBC Upgrades IMI And Downgrades Rotork
UK BROKER RATINGS SUMMARY: RBC Upgrades IMI And Downgrades Rotork
Clinigen FY revenues continue to rise, profit growth slowed by Covid-19
(Sharecast News) - Pharmaceutical group Clinigen warned full-year profit growth would be at the lower end of guidance as a result of the Covid-19 pand...
Clinigen gets orphan drug designation for 'aldesleukin' in the US
(Sharecast News) - Pharmaceutical services company Clinigen Group announced on Monday that the US Food and Drug Administration (FDA) Office of Orphan ...
Monday broker round-up
(Sharecast News) - Kingfisher: RBC Capital Markets reiterates outperform with a target price of 275.0p
Clinigen Gets US Orphan Drug Designation For ALS Treatment Aldesleukin
Clinigen Gets US Orphan Drug Designation For ALS Treatment Aldesleukin
Sunday newspaper round-up: Two meters, Rolls Royce, Clinigen
(Sharecast News) - Senior scientists have reported flaws in an influential World Health Organization-commissioned study into the risks of coronavirus ...
Follow the stocks
